ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation
|
|
k2rictor
|
15 |
5.3K |
0 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
15
|
5.3K
|
0
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
k2rictor
|
113 |
46K |
14 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
113
|
46K
|
14
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Vitrolife distribution agreement expands into Canada and NZ
|
|
k2rictor
|
81 |
23K |
2 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
81
|
23K
|
2
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Vitrolife distribution agreement expands into Canada and NZ
|
|
k2rictor
|
81 |
23K |
5 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
81
|
23K
|
5
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Board and executive transition and capital raise
|
|
k2rictor
|
12 |
4.2K |
4 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
12
|
4.2K
|
4
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Board and executive transition and capital raise
|
|
k2rictor
|
12 |
4.2K |
11 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
12
|
4.2K
|
11
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
5 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
50
|
14K
|
5
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
0 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
50
|
14K
|
0
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
1 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
50
|
14K
|
1
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
2 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
50
|
14K
|
2
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
0 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
50
|
14K
|
0
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
2 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
50
|
14K
|
2
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
1 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
50
|
14K
|
1
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Investor Presentation Sept 23
|
|
k2rictor
|
50 |
14K |
6 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
50
|
14K
|
6
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
7 |
23/09/23 |
23/09/23 |
ASX - By Stock
|
1.7K
|
661K
|
7
|
|
ASX - By Stock
|
MEM |
Re:
Ann: In-Depth Investor Webinar Presentation
|
|
k2rictor
|
6 |
1.7K |
0 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
6
|
1.7K
|
0
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Response to ASX Price Query
|
|
k2rictor
|
11 |
4.7K |
11 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
11
|
4.7K
|
11
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Response to ASX Price Query
|
|
k2rictor
|
11 |
4.7K |
10 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
11
|
4.7K
|
10
|
|
ASX - By Stock
|
PCK |
Re:
Ann: PainChek A$3.55m Placement
|
|
k2rictor
|
38 |
14K |
17 |
14/09/23 |
14/09/23 |
ASX - By Stock
|
38
|
14K
|
17
|
|
ASX - By Stock
|
PCK |
Re:
Ann: PainChek A$3.55m Placement
|
|
k2rictor
|
38 |
14K |
3 |
14/09/23 |
14/09/23 |
ASX - By Stock
|
38
|
14K
|
3
|
|
ASX - By Stock
|
PCK |
Re:
Ann: US nursing home study to pave way for FDA De Novo clearance
|
|
k2rictor
|
19 |
7.1K |
4 |
26/08/23 |
26/08/23 |
ASX - By Stock
|
19
|
7.1K
|
4
|
|
ASX - By Stock
|
PCK |
Re:
Ann: US nursing home study to pave way for FDA De Novo clearance
|
|
k2rictor
|
19 |
7.1K |
5 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
19
|
7.1K
|
5
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Vitrolife sign Felix distribution agreement for Japanese mkt
|
|
k2rictor
|
7 |
3.3K |
6 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
7
|
3.3K
|
6
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
6 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
1.7K
|
661K
|
6
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
k2rictor
|
12 |
4.2K |
6 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
12
|
4.2K
|
6
|
|
ASX - By Stock
|
MEM |
Re:
Ann: New Patents granted for Felix System
|
|
k2rictor
|
13 |
5.3K |
5 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
13
|
5.3K
|
5
|
|
ASX - By Stock
|
MEM |
Re:
Q&A interview with Director of Business Development Dr David Ali
|
|
k2rictor
|
18 |
8.8K |
6 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
18
|
8.8K
|
6
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
3 |
20/06/23 |
20/06/23 |
ASX - By Stock
|
1.7K
|
661K
|
3
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
6 |
20/06/23 |
20/06/23 |
ASX - By Stock
|
1.7K
|
661K
|
6
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
7 |
16/06/23 |
16/06/23 |
ASX - By Stock
|
1.7K
|
661K
|
7
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
11 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
1.7K
|
661K
|
11
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Ethos Laboratories Distribution Agreement
|
|
k2rictor
|
21 |
6.1K |
13 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
21
|
6.1K
|
13
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
12 |
12/05/23 |
12/05/23 |
ASX - By Stock
|
1.7K
|
661K
|
12
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
k2rictor
|
22 |
7.2K |
4 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
22
|
7.2K
|
4
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
k2rictor
|
22 |
7.2K |
9 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
22
|
7.2K
|
9
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
k2rictor
|
22 |
7.2K |
2 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
22
|
7.2K
|
2
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
k2rictor
|
22 |
7.2K |
4 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
22
|
7.2K
|
4
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
k2rictor
|
22 |
7.2K |
3 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
22
|
7.2K
|
3
|
|
ASX - By Stock
|
PCK |
Re:
PainChek General Discussion
|
|
k2rictor
|
20K |
16M |
3 |
17/04/23 |
17/04/23 |
ASX - By Stock
|
20K
|
16M
|
3
|
|
ASX - By Stock
|
PCK |
Re:
Media Thread
|
|
k2rictor
|
1.7K |
661K |
4 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
1.7K
|
661K
|
4
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Japan first commercial sale and first baby born using Felix
|
|
k2rictor
|
28 |
8.5K |
3 |
03/04/23 |
03/04/23 |
ASX - By Stock
|
28
|
8.5K
|
3
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Experienced fertility expert appointed Operations Director
|
|
k2rictor
|
13 |
3.1K |
1 |
31/03/23 |
31/03/23 |
ASX - By Stock
|
13
|
3.1K
|
1
|
|
ASX - By Stock
|
MEM |
Re:
Ann: KOL testings demonstrate Felix System outperforms DGC
|
|
k2rictor
|
29 |
9.3K |
0 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
29
|
9.3K
|
0
|
|
ASX - By Stock
|
MEM |
Re:
Ann: KOL testings demonstrate Felix System outperforms DGC
|
|
k2rictor
|
29 |
9.3K |
0 |
08/02/23 |
08/02/23 |
ASX - By Stock
|
29
|
9.3K
|
0
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
k2rictor
|
29 |
10K |
5 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
29
|
10K
|
5
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Results of Meeting
|
|
k2rictor
|
14 |
7.2K |
5 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
14
|
7.2K
|
5
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Results of Meeting
|
|
k2rictor
|
14 |
7.2K |
1 |
11/01/23 |
11/01/23 |
ASX - By Stock
|
14
|
7.2K
|
1
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Results of Meeting
|
|
k2rictor
|
14 |
7.2K |
3 |
11/01/23 |
11/01/23 |
ASX - By Stock
|
14
|
7.2K
|
3
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Change of Director's Interest Notice - AG
|
|
k2rictor
|
6 |
2.3K |
9 |
05/01/23 |
05/01/23 |
ASX - By Stock
|
6
|
2.3K
|
9
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Change of Director's Interest Notice - AG
|
|
k2rictor
|
6 |
2.3K |
1 |
05/01/23 |
05/01/23 |
ASX - By Stock
|
6
|
2.3K
|
1
|
|